Navigation Links
ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study

- Pending Final Analysis of the Results, ISTA Plans to Initiate Phase III Studies in Dry Eye in 2008 -

IRVINE, Calif., May 31, 2007 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced positive results from the preliminary analysis of the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye syndrome. Patients in the ecabet sodium group achieved a strong trend in the objective sign of blink rate. In addition, patients in the ecabet sodium group reported a strong trend in the Ocular Symptom Disease Index (OSDI) and a positive trend in the subjective assessment of patients' most bothersome symptom. Strong and positive trends are used to confirm observations from previous clinical ecabet sodium studies and to serve as indicators of potential efficacy endpoints in Phase III studies. While ISTA's Phase IIb study was not powered to show statistical significance, ecabet sodium did achieve statistical significance in the OSDI assessment. There were no reports of serious ocular adverse events compared with placebo. Further analyses of the Phase IIb study results are ongoing.

"We are very encouraged by the Phase IIb study's preliminary results, as they support our belief that ecabet has the ability to treat signs and symptoms of dry eye syndrome," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA. "Our key objectives for this study were to validate our protocol and to screen out non-responders. We were successful in doing both. In addition, we showed positive trending in one sign and one symptom, plus achieved statistical significance in a second symptom, all in a single study. Ecabet sodium may provide advantages over other dry eye products and product candidates, as we believe the drug not only improves the quality of tears by enhancing mucin production, but may increase the quantity of tears produced. Although not
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... 23, 2013  Hologic, Inc. (Hologic or the ... developer, manufacturer and supplier of premium diagnostics, medical ... on serving the healthcare needs of women, today ... a U.S. clinical practice comparing breast cancer screening ... conventional 2D mammography alone showed a significant reduction ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
... AMGN ) reported adjusted earnings per share (EPS) of ... percent compared to $1.05 for the fourth quarter of 2009.  Adjusted ... quarter of 2010 compared to $1,065 million in the fourth quarter ... versus $4.91 in 2009, a 6 percent increase.  Full year 2010 ...
... Athersys, Inc. (Nasdaq: ATHX ), a ... January 11th Retail Investor Conferences.com presentation is available ... and Chief Executive Officer of Athersys, presented to ... To view the archived presentation, click ...
Cached Medicine Technology:Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 2Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 3Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 4Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 5Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 6Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 7Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 8Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 9Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 10Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 11Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 12Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 13Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 14Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 15Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 16Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 17Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21 18Athersys, Inc. - Retail Investor Conferences.com Presentation Now Available Online 2
(Date:5/24/2013)... 2013 Mr. Brian Su, CEO of ... EB-5 Investment Summit: Dealmakers Conference in Long Beach, California ... on exploring alternative finance through EB-5 immigrant investors program. ... economic information, and updates to project developers, regional center ... , "Our goal is to assist EB-5 projects ...
(Date:5/24/2013)... New York, NY (PRWEB) May 24, 2013 ... of Yahoo Commerce VP, Brandon Huff as Executive Vice ... ran its commerce business units, which represented a large ... will lead digital growth as Dwell develops a fully-integrated ... him a decade of experience monetizing digital content for ...
(Date:5/24/2013)... Mike Stoler believes that there is much ... in New York. That’s why he hosts “Building ... TV. And that’s why he invited Robert Glazer, ... (ENTA)—the largest single specialty practice in the greater New ... audiology specialists and sub-specialists service communities throughout New York ...
(Date:5/24/2013)... -- Low-income, minority parents have more realistic views ... open to vaccinating their daughters against the cervical ... contends. Conversely, white, middle-class parents are more ... according to researchers from the Boston University School ... an HPV-related cancer each year, many of which ...
(Date:5/24/2013)... According to the National Institutes of Health, Stevens Johnson ... that affects the skin and mucous membranes. SJS occurs ... of 30 (i). In the early stages SJS presents ... SJS advances, it affects the mucous membranes such as the ... of the eye causes conjunctivitis (pink eye). Inflammation of ...
Breaking Medicine News(10 mins):Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3
... could benefit from a slight forward jaw adjustment, ... in,the American Academy of Dental Sleep Medicine is advocating ... in 15 Americans who suffer alarming,and sometimes deadly sleep ... a,first line of treatment., "It,s just amazing that ...
... and the School of Medicine have devised a micro-scale tool - ... complexities of the brain. The system should help scientists better understand ... nervous system. , A report on the work appears as ... journal Lab on a Chip. , The chip weve developed ...
... Scientists from the Wildlife Conservation Society and Max Planck ... photographs of gorillas performing face-to-face copulation in the wild. ... have been observed and photographed mating in such a ... conducted in a forest clearing in Nouabal-Ndoki National Park ...
... 12 Perrigo Company,(Nasdaq: PRGO ; TASE) ... the U.S. Food and Drug Administration (FDA) for ... 10 mg, Calcium,Carbonate 800 mg, and Magnesium Hydroxide ... be marketed under store brand labels and is ...
... 12 In order to promote and,increase sun ... and,Dermatologic Surgery (FSDDS) is holding an essay contest ... Florida Sun Defense Essay Contest is,designed to help ... importance of sun safety. It is being co-sponsored ...
... For children who suffer from obstructive sleep apnea (OSA), ... successful in solving sleep problems for 80 to 90 percent ... The study is the largest to date that looks at ... after they have surgery, using both preoperative and postoperative sleep ...
Cached Medicine News:Health News:Dental Devices Offer a Simple Solution for Sleep 2Health News:Dental Devices Offer a Simple Solution for Sleep 3Health News:'Lab on a chip' mimics brain chemistry 2Health News:Study garners unique mating photos of wild gorillas 2Health News:Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets 2Health News:FSDDS Creates New Sun Defense Essay Contest Throughout Florida Elementary Schools 2Health News:Surgery improves quality of life for children with sleep apnea 2Health News:Surgery improves quality of life for children with sleep apnea 3
... dryer is an electrophoresis gel vacuum dryer that ... dries these gels onto cellophane or filter paper ... elements which heat gels from above. The drying ... V unit includes power cord, porous gel support, ...
... constant voltage power supply, the 105 is very ... range switch control the output, which is variable ... One, two-position switch toggles the bright LED display ... 105 is equipped with an over current detector ...
... simple techniques such as submarine electrophoresis and ... IEF, the Series 90 Programmable Power Supplies ... 90 Programmable Power Supplies are available in ... 6000V., All models operate in constant voltage, ...
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Medicine Products: